What is ImpediMed?
Founded in 1999 and headquartered in Queensland, Australia, ImpediMed specializes in the development and distribution of medical devices that utilize bioimpedance spectroscopy. The company's core technology provides clinicians with precise, non-invasive data regarding patient fluid status, a critical metric in managing chronic conditions and post-surgical recovery. As a market leader, ImpediMed bridges the gap between complex physiological data and actionable clinical insights, maintaining a robust portfolio of diagnostic hardware that supports healthcare providers in delivering superior patient outcomes through data-driven monitoring protocols.
How much funding has ImpediMed raised?
ImpediMed has raised a total of $86.9M across 4 funding rounds:
Other Financing Round
$3.4M
Stock Offering
$11.5M
Share Placement
$57M
Other Financing Round
$15M
Other Financing Round (2006): $3.4M with participation from Starfish Ventures
Stock Issuance/Offering (2007): $11.5M, investors not publicly disclosed
Share Placement (2016): $57M, investors not publicly disclosed
Other Financing Round (2025): $15M featuring Armentum Partners and SWK Holdings
Key Investors in ImpediMed
Armentum Partners
Armentum Partners is a full-service investment bank specializing in debt capital advisory services, primarily for technology and healthcare companies across North America, Europe, and Australia.
SWK Holdings
Founded in 1996, SWK Holdings is a life science specialty finance company that is focused on opportunities in the global healthcare sector, providing innovative capital solutions.
Starfish Ventures
Starfish Ventures is a venture capital manager based in Australia, specializing in high growth technology businesses, particularly in information technology and life sciences.
What's next for ImpediMed?
With the successful closure of this major enterprise-level funding round, ImpediMed is well-positioned to accelerate its strategic growth initiatives. The company is expected to focus on scaling its global distribution networks and enhancing its BIS technology suite to meet the evolving demands of the healthcare sector. By aligning with specialized financial partners, ImpediMed aims to optimize its capital structure, ensuring long-term sustainability and continued innovation in the medical device landscape. Future efforts will likely prioritize the integration of its diagnostic platforms into broader digital health ecosystems, further cementing its role as an essential partner in modern clinical diagnostics.
See full ImpediMed company page
